An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Inclusion Criteria:

- Able to comply with the study protocol, in the investigator's judgment

- Completion of Study GA30044 up to 48 weeks

- Acceptable safety and tolerability during Study GA30044 as determined by the
investigator

Exclusion Criteria:

- Met protocol-defined treatment-stopping criteria during Study GA30044

- An adverse event in Study GA30044 that required permanent discontinuation of study
drug

- In the opinion of the investigator, any new, significant, uncontrolled comorbidity or
new clinical manifestation (related to SLE or not) that requires medications not
allowed in this protocol; or could put the participant at undue risk from a safety
perspective

- Any uncontrolled or clinically significant laboratory abnormality that would affect
safety, interpretation of study data, or the participant's participation in the study
in the opinion of the investigator in consultation with the Medical Monitor